Dealmakers in healthcare have found a new rhythm after two turbulent years. Capital flows back, but investors now demand tighter underwriting, deeper due diligence, and realistic growth forecasts. According to Matthew Brohm of Arnall Golden Gregory, only sponsors who adapt these standards close deals.

Brohm outlines five practical rules that separate the successful from the short‑shanked. The first rule stresses rigorous valuation checks; the second pushes for transparent revenue projections. A third rule highlights the necessity of aligning growth plans with proven market data, while the fourth and fifth focus on disciplined negotiation tactics and post‑deal integration.

These guidelines signal a shift toward more disciplined, data‑driven M&A in the sector. For investors, the message is clear: only firms that adopt this updated playbook will secure favorable terms and sustainable returns in 2026.